Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

At the start of 2024, Virtualware launched a Strategic Plan to expand its North American footprint over the next three years. North American sales represented 36% of total revenue in 2024. The company ...

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

In an editorial, J. Mocco, MD, of Mount Sinai Health System in New York City, characterized the DISTAL and ESCAPE-MeVO ...

Twenty-five years ago, the bestseller “The Tipping Point” turned Malcolm Gladwell into a household name. Describing “the critical mass, the threshold, the boiling point,” Gladwell illustrates ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...